Anti-lipolysis-stimulated lipoprotein receptor monoclonal antibody as a novel therapeutic agent for endometrial cancer.
Yoshikazu NagaseKosuke HiramatsuMasashi FunauchiMayu ShiomiTatsuo MasudaMamoru KakudaSatoshi NakagawaAi MiyoshiShinya MatsuzakiEiji KobayashiToshihiro KimuraSatoshi SeradaYutaka UedaTetsuji NakaTadashi KimuraPublished in: BMC cancer (2022)
Our results suggest that LSR contributes to tumor growth, invasion, metastasis, and poor prognosis of EC through MAPK signaling. Anti-LSR mAb is a potential therapeutic agent for EC.